On November 22, 2022, Pardalis Technology Licensing, LLC — a patent assertion entity — filed suit against International Business Machines Corporation in the Eastern District of Texas, asserting seven U.S. patents against a broad range of IBM’s blockchain-related products. The accused products spanned IBM’s entire blockchain commercial portfolio, including IBM Food Trust, IBM Blockchain World Wire, IBM Digital Health Pass, and multiple versions of the IBM Blockchain Platform. The asserted patents cover technologies relating to data management, structured data access, and network-based information processing.

On November 21, 2024 — exactly two years after filing — the parties jointly moved for dismissal under Rule 41(a)(2) and (c). The court granted the motion the same day. Critically, the dismissal is asymmetric: all of Pardalis’s infringement claims are dismissed with prejudice, meaning Pardalis is permanently barred from re-filing those same claims against IBM on those patents. IBM’s counterclaims — which typically include invalidity and non-infringement defenses — were dismissed without prejudice, preserving IBM’s ability to revive them if Pardalis were ever to assert the patents again through another vehicle.

The two-year litigation timeline ending in a joint dismissal — with no public settlement terms disclosed — is consistent with a confidential resolution between the parties, though the public record is silent on financial terms. The with-prejudice dismissal of Pardalis’s claims is a structurally favorable outcome for IBM, eliminating future re-assertion risk on these seven patents. What drove the resolution — whether claim construction rulings, IPR petitions, or commercial negotiations — is not determinable from the public docket alone.